Company intelligence / Profile preview

Biomedizinische Forschung & Bio-Produkte

Ownership: Private
Development stage: Phase 2

Overview

A recombinant TSST-1 variant vaccine (BioMed rTSST-1) rapidly induced high and persistent neutralizing antibody titers against superantigens in healthy adults, demonstrated after second immunization with durable immune responses; phase 2 study complete[5][10].

Therapeutic areas: Infectious Diseases
Modalities: VaccineProtein
Industry: Academic Hospital/University/Research

Drug pipeline

2 assets

TSS vaccine

Phase 2

Indications: Toxic shock syndrome

1 more asset in the full pipeline.

Request access →

Partnerships

Medical University of Vienna

Beyond the preview

Go deeper on Biomedizinische Forschung & Bio-Produkte.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biomedizinische Forschung & Bio-Produkte.

Explore the full profile